Locally advanced Urothelial Carcinoma

DrugDrug NameDrug Description
DB11595AtezolizumabA monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.
DB11714DurvalumabAn antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer.
DB09035NivolumabA PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
DB09037PembrolizumabA PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.
DrugDrug NamePhaseStatusCount
DB08875Cabozantinib1Recruiting1
DB13007Enfortumab vedotin1Not Yet Recruiting1
DB13007Enfortumab vedotin1Recruiting1
DB12147Erdafitinib1Not Yet Recruiting1
DB09037Pembrolizumab1Recruiting1
DB09143Sonidegib1Recruiting1
DB08871Eribulin1 / 2Active Not Recruiting1
DB09037Pembrolizumab1 / 2Recruiting2
DB11942Selinexor1 / 2Recruiting1
DB12887Tazemetostat1 / 2Recruiting1
DB09035Nivolumab2Not Yet Recruiting1
DB09037Pembrolizumab2Recruiting1
DB00571Propranolol2Recruiting1
DB11595Atezolizumab3Recruiting1
DB11945Avelumab3Recruiting1
DB11714Durvalumab3Recruiting1
DB09035Nivolumab3Recruiting1
DB09037Pembrolizumab3Active Not Recruiting1
DB09037Pembrolizumab3Recruiting1